USPSTF Transparency and Accountability Act of 2013

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143. Support the Drug Supply Chain Security Act, S.B. 959. Support the Orphan Drug Tax Credit (ODTC). Support House and Senate efforts to require HHS to adopt standards ensuring electronic health record systems are interoperable by 2017 or another date certain, as well as provisions to prevent the blocking of information necessary to treat a patient. RetireSafe also supports strong privacy protections in this regard. Support a "safety first" unique naming policy for any and all biosimilar drugs pending market approval. Urged the FTC and the FDA to place patient safety and consumer protection above all other considerations regarding biosimilar drugs.

Client expense: $23,564 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), President of the U.S., SENATE

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143. Support the Drug Supply Chain Security Act, S.B. 959. Support the Orphan Drug Tax Credit (ODTC). Support House and Senate efforts to require HHS to adopt standards ensuring electronic health record systems are interoperable by 2017 or another date certain, as well as provisions to prevent the blocking of information necessary to treat a patient. RetireSafe also supports strong privacy protections in this regard. Support a "safety first" unique naming policy for any and all biosimilar drugs pending market approval. Urged the FTC and the FDA to place patient safety and consumer protection above all other considerations regarding biosimilar drugs.

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143. Support the Drug Supply Chain Security Act, S.B. 959. Support the Orphan Drug Tax Credit (ODTC). Support House and Senate efforts to require HHS to adopt standards ensuring electronic health record systems are interoperable by 2017 or another date certain, as well as provisions to prevent the blocking of information necessary to treat a patient. RetireSafe also supports strong privacy protections in this regard. Support a "safety first" unique naming policy for any and all biosimilar drugs pending market approval. Urged the FTC and the FDA to place patient safety and consumer protection above all other considerations regarding biosimilar drugs.

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143. Support the Drug Supply Chain Security Act, S.B. 959. Support the Orphan Drug Tax Credit (ODTC). Support House and Senate efforts to require HHS to adopt standards ensuring electronic health record systems are interoperable by 2017 or another date certain, as well as provisions to prevent the blocking of information necessary to treat a patient. RetireSafe also supports strong privacy protections in this regard. Support a "safety first" unique naming policy for any and all biosimilar drugs pending market approval. Urged the FTC and the FDA to place patient safety and consumer protection above all other considerations regarding biosimilar drugs.

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143. Support the Drug Supply Chain Security Act, S.B. 959. Support the Orphan Drug Tax Credit (ODTC). Support House and Senate efforts to require HHS to adopt standards ensuring electronic health record systems are interoperable by 2017 or another date certain, as well as provisions to prevent the blocking of information necessary to treat a patient. RetireSafe also supports strong privacy protections in this regard.

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143. Support the Drug Supply Chain Security Act, S.B. 959. Support the Orphan Drug Tax Credit (ODTC). Support House and Senate efforts to require HHS to adopt standards ensuring electronic health record systems are interoperable by 2017 or another date certain, as well as provisions to prevent the blocking of information necessary to treat a patient. RetireSafe also supports strong privacy protections in this regard.

HR 2143

Client expense: $15,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143. Support the Drug Supply Chain Security Act, S.B. 959. Support the Orphan Drug Tax Credit (ODTC).

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143. Support the Drug Supply Chain Security Act, S.B. 959. Support the Orphan Drug Tax Credit (ODTC).

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143.

Commented to the Secretary of Health and Human Services on the Proposed Rule "Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing." Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace "limitations on amount, duration, and scope" and "adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs," as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that "medically frail" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs. Oppose the use of "cost-effectiveness standards" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA). Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary. Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates "a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes." Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 "Frequently Asked Questions about the ACA" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year. Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS) "Discovering New Therapeutic Uses for Existing Molecules Initiative," especially as it applies to the enhanced development of new treatments for Alzheimer's Disease. Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143.